Date:12/20/2012

reast cancer has allowed for a deeper understanding of the disease, and this paper moves us steps closer to being able to follow a similar trajectory with prostate cancer. Today, such an understanding and a formidable testing ground for new therapies is lacking for this disease," Dr. Pestell said. "With this new oncogene-specific prostate cancer molecular signature, we have a valuable prognostic and diagnostic resource that could help change the way we manage and treat prostate cancer."

'/>"/>

Contact: Steve Graff stephen.graff@jefferson.edu 215-955-5291 Thomas Jefferson University Source:Eurekalert

0 GOOD

Page: 1 2 3
Related biology technology :

1. Changing our material future, layer by layer
2. Fast forward to the past: NASA technologists test game-changing data-processing technology
3. A new take on the Midas touch -- changing the color of gold
4. New Competitive Arena Emerges for Pharmaceutical Companies in Healthcares Changing Payment Landscape, Finds PwC Health Research Institute Study
5. Europe Anesthesia and Respiratory Devices Market Outlook to 2018 - Respiratory Devices, Respiratory Measurement Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others
6. Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics Human Pilot Study
7. PharmSource Lead Sheet Adds Coverage of Medical Devices and Diagnostics
8. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
9. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
10. Quest Diagnostics Clinical Trials Biorepository Accredited by the College of American Pathologists
11. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum